Diabetic cardiomyopathy （DCM） is a common chronic complication of diabetes， categorized as consumptive thirst in traditional Chinese medicine （TCM）， and it subsequently gives rise to chest impediment. DCM is characterized by a complex pathogenesis and exhibits long-term progression with poor prognosis in clinical practice. Astragali Radix， as a medicinal material with edible value， possesses diverse active components including saponins， polysaccharides， and flavonoids. It has the effects of tonifying Qi， elevating Yang， promoting fluid production， nourishing blood， expressing toxin， and expelling pus. Modern pharmacological studies have confirmed that Astragali Radix and its active components exert therapeutic effects in various aspects such as inhibition of inflammation， alleviation of stress injury， regulation of programmed cell death， modulation of glucose and lipid metabolism， inhibition of myocardial fibrosis， and regulation of gut microbiota and metabolites， treating DCM in a multi-component， multi-target， and multi-pathway manner. The compatibility of Astragali Radix exerts both synergistic and antagonistic effects. The compound preparations and extracts of Astragali Radix are widely used in clinical practice， and the development of novel nano and gel materials and extracellular vesicles helps to improve the oral bioavailability， providing more possibilities for the clinical application of Astragali Radix in DCM， though its potential for clinical translation requires ongoing exploration. This review summarizes the TCM theoretical basis of Astragali Radix in the treatment of DCM， and integrates modern pharmacological research results to delve into the effects and mechanisms of the herb combinations， compound preparations， extracts， and new composite materials of Astragali Radix in the treatment of DCM， aiming to provide a reference for in-depth research and new drug development of Astragali Radix for DCM.

Objective To explore targeted time management to shorten the time from arriving hospital to thrombolysis ( DNT ) . Methods A total of 42 suspected acute ischemic stroke ( AIS ) patients were underwent the targeted time management from pre-hospital until emergency thrombolysis while other 24 cases from 120 to hospital started from the time arriving Emergency Department. The complete rate of targeted time management and DNT compared with before management. Results In the control group, the hospital received 42 pre-hospital patients suspected with AIS in 3 hrs, and completed all targets 31 cases with pass rate of 73. 8%; the experimental group acquired 38 cases and achieved targets 35 cases with pass rate of 92. 1% (χ2 =4. 625,P<0. 05). In the experimental group, the pass rate of pre-hospital Emergency Department, CT detection, thrombolysis preparation were 100% (38/38), 94. 7% (18/19), 94. 7%(18/19) higher than 61. 9% (26/42), 55. 6% (10/18), 58. 8% (10/17) (χ2 =18. 095,5. 727,4. 779;P <0. 05). A total of 17 cases underwent thrombolysis with DNT of ( 68. 65 ± 23. 75 ) min while 19 cases in the experimental group with DNT of (35.50±2.98)min(Z=5.106,P<0.01),and4casescomingfrom120withDNTof(46.40±5.68) min (Z= -4. 092,P <0. 05). Conclusions To utilize pre-hospital time reasonable, we make the thrombolysis process early, regulate the process, manage each segment time targeted, find out and improve the reasons for overdue segment, make clear individual responsibility, which can shorten the DNT and be benefit patients.